November 25, 2024

AstraZeneca’s Truqap Achieves Phase 3 Success in Prostate Cancer, Paving Way for Label Expansion

5 months ago talkbio0Tagged Antiandrogen therapy, AstraZeneca, CAPItello-281, Hormone Responsive, Malignant neoplasm of prostate, Metastatic to, Phase 3 trial, Progression-Free Survival, PTEN-deficient, Radiographic, rPFS, Truqap

AstraZeneca, Truqap, prostate cancer, Phase 3 trial, CAPItello-281, PTEN-deficient, metastatic hormone-sensitive prostate cancer, radiographic progression-free survival (rPFS), abiraterone, androgen deprivation therapy (ADT)

Navigating JPM Week 2024: Insights and Opportunities in Biopharma

5 months ago talkbio0Tagged Biopharma, deal-making, Industry, Investments, IPOs, JPM, M&A, Network, regulatory, trends qualifier

JPM Week 2024, Biopharma, Industry Insights, Networking, Deal-making, Investment, M&A, IPOs, Regulatory Trends

FDA Approves Attruby (Acoramidis) for ATTR-CM, Offering New Hope for Patients with Transthyretin Cardiac Amyloidosis

5 months ago talkbio0Tagged Acoramidis, Approved, ATTR-CM, Attruby, BridgeBio Pharma, Heart Diseases, Prealbumin, Senile cardiac amyloidosis, United States Food and Drug Administration

Attruby, Acoramidis, FDA Approval, ATTR-CM, Transthyretin Cardiac Amyloidosis, BridgeBio Pharma, Heart Disease Treatment

Bristol Myers Squibb Announces Additional Layoffs in New Jersey Amid Cost-Cutting Efforts

5 months ago talkbio0Tagged cost-cutting, Drug Industry, Myers, New Jersey, squibb

Bristol Myers Squibb, layoffs, New Jersey, cost-cutting, pharmaceutical industry

Adcendo Secures $135 Million Funding for Antibody-Drug Conjugate Pipeline

5 months ago talkbio0Tagged ADC, Adcendo, Antibody-Drug, Holdings, pipeline, therapeutic autologous dendritic cells

Adcendo, Novo Holdings, ADC pipeline, funding, biotech, antibody-drug conjugate

Trump Nominates Renowned Surgeon Martin Makary as FDA Commissioner

5 months ago talkbio0Tagged Commissioner, Donald Trump, Hopkins, Johns, Makary, Martin, nomination, Surgeon, United States Food and Drug Administration

Martin Makary, FDA Commissioner, Donald Trump, Johns Hopkins, Surgeon, Nomination

Biohaven’s Taldefgrobep Alfa Misses Primary Endpoint in Phase 3 SMA Trial, Eyes FDA Discussions and Obesity Indication

5 months ago talkbio0Tagged Discussion (procedure), Indication of (contextual qualifier), Obesity, Phase 3 trial, Spinal Muscular Atrophy, Talditercept alfa, United States Food and Drug Administration

Biohaven, Taldefgrobep Alfa, Spinal Muscular Atrophy (SMA), Phase 3 Trial, FDA Discussions, Obesity Indication

Merck Advances with Winrevair: Positive Phase III Results in Severe Pulmonary Arterial Hypertension (PAH) Study

5 months ago talkbio0Tagged Cardiovascular system, Merck, Morbidity - disease rate, Mortality Vital Statistics, PAH, Phase III, Pulmonary arterial hypertension, Winrevair, ZENITH study

Merck, Winrevair, PAH, Phase III, ZENITH study, pulmonary arterial hypertension, cardiovascular drug, morbidity, mortality

Advancements in Hematology: Shaping the Future of Blood Disorder Diagnosis and Treatment

5 months ago talkbio0Tagged Anemia, Sickle Cell, Clinical Practice Guideline, gene therapy, Hematological Disease, Hematology (discipline), Improvement, Quality

Hematology, Blood Disorders, Sickle Cell Disease, Gene Therapy, Clinical Guidelines, Quality Improvement

Biopharma Industry Braces for Uncertainty Under Trump’s Second Term: Impact on Vaccines and M&A Deals

5 months ago talkbio0Tagged Biopharma Industry, Changing, FTC, Health Policy, M&A, Policy, Regulation, second, Trump 's, United States Federal Trade Commission, Vaccines

Trump’s second term, Biopharma industry, Vaccine regulation, Robert F. Kennedy Jr., M&A deals, FTC policy changes, Healthcare policy uncertainty